NASDAQ: MYMDMymd Pharmaceuticals Inc Stock
$2.50-0.02 (-0.79%)
Updated Apr 19, 2024
MYMD Price
$2.50
Fair Value Price
$1.71
Market Cap
$5.39M
52 Week Low
$2.00
52 Week High
$70.50
P/E
-0.47x
P/B
0.44x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$4.00M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.41
Operating Cash Flow
-$13M
Beta
1.49
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
MYMD Overview
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MYMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MYMD ($2.50) is overvalued by 46.5% relative to our estimate of its Fair Value price of $1.71 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MYMD ($2.50) is not significantly undervalued (46.5%) relative to our estimate of its Fair Value price of $1.71 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MYMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MYMD due diligence checks available for Premium users.
Be the first to know about important MYMD news, forecast changes, insider trades & much more!
MYMD News
Valuation
MYMD fair value
Fair Value of MYMD stock based on Discounted Cash Flow (DCF)
Price
$2.50
Fair Value
$1.71
Overvalued by
46.50%
MYMD ($2.50) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MYMD ($2.50) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MYMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MYMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.47x
Industry
15.81x
Market
40.51x
MYMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.44x
Industry
5.74x
MYMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MYMD's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.4M
Profit Margin
0%
MYMD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$17.9M
Liabilities
$5.1M
Debt to equity
0.41
MYMD's short-term assets ($5.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MYMD's short-term assets ($5.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MYMD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MYMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.9M
Investing
$5.9M
Financing
-$1.6M
MYMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MYMD vs Biotech Stocks
Mymd Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.